Efficacy News and Research

RSS
AVEO second-quarter total revenues increase to $15.6 million

AVEO second-quarter total revenues increase to $15.6 million

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

ACT responds to FDA queries on Phase I/II study using ES cell derived retinal cells to treat SMD

ACT responds to FDA queries on Phase I/II study using ES cell derived retinal cells to treat SMD

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

NDS Surgical Imaging introduces ConnectOR G2 visualization and informatics platform

NDS Surgical Imaging introduces ConnectOR G2 visualization and informatics platform

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

FDA approves Cuvposa Oral Solution for chronic severe drooling in children

FDA approves Cuvposa Oral Solution for chronic severe drooling in children

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Pain Therapeutics second-quarter collaboration revenue decreases to $0.1 million

Pain Therapeutics second-quarter collaboration revenue decreases to $0.1 million

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

BiondVax receives 2010 European Influenza Vaccines Technology Innovation Award

BiondVax receives 2010 European Influenza Vaccines Technology Innovation Award

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron second-quarter total revenues increase to $115.9 million

New York Times examines questions left unanswered by microbicide trial

New York Times examines questions left unanswered by microbicide trial

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

U.S. Marshals seize FastSize Extender devices and FastSize EQM Erectile Quality Monitor devices

U.S. Marshals seize FastSize Extender devices and FastSize EQM Erectile Quality Monitor devices

Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients

Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients

InterMune second-quarter total revenue decreases to $5.9 million

InterMune second-quarter total revenue decreases to $5.9 million

Progenra receives Official Notice of Allowance for screening platform

Progenra receives Official Notice of Allowance for screening platform

QLT second-quarter total revenue increases 15.4% to $12.4 million

QLT second-quarter total revenue increases 15.4% to $12.4 million

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.